Last reviewed · How we verify
NCT07278921: MosuOSSHSR
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
trial testing Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in 25 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Andrés José Maria Ferreri |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 December 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Mosunetuzumab (MOSUNETUZUMAB) — full drug profile →
Conditions studied
- Relapsed/Refractory Follicular Lymphoma — all drugs for Relapsed/Refractory Follicular Lymphoma →
Sponsor
Andrés José Maria Ferreri — full company profile →
Who can join
18 and older, any sex, with Relapsed/Refractory Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07278921
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mosunetuzumab
Trials testing the same drug.
- NCT07052695 — Mosunetuzumab for CLL MRD Clearance · Phase 1, PHASE2 · recruiting
- NCT06948786 — Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri · Phase 2 · recruiting
- NCT07031700 — A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL · Phase 2 · not yet recruiting
- NCT06563505 — A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma · Phase 2 · recruiting
- NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
Other recruiting trials for Relapsed/Refractory Follicular Lymphoma
Currently open trials in the same condition.
- NCT07418190 — Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Ref · Phase 2 · recruiting
- NCT06149286 — A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Len · Phase 3 · recruiting
- NCT04224493 — A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenal · Phase 3 · recruiting
- NCT04587388 — Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry · recruiting
Other Andrés José Maria Ferreri trials
Trials by the same sponsor.
- NCT07393204 — Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL · active not recruiting
- NCT07181785 — Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07278921 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Andrés José Maria Ferreri
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278921.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing